Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
lunes, noviembre 02
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Quest Diagnostics Inc
DGX
NYSE
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$250.81
-1.01
-0.4%
Últ. Act.: Nov 2, 4:00 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Dividendos
Comparar
Opciones
Informe de acciones
Quest Diagnostics Financials
Quest Diagnostics (DGX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Quest Diagnostics Bumps Guidance While Managing Quanum System Breach
Quest Diagnostics tops Q3 estimates, raises full-year 2026 guidance, and addresses an unauthorized Quanum LSM cybersecurity event.
Vandana Singh
PRO
Quest Diagnostics Raises FY2026 GAAP EPS Guidance from $9.97-$10.17 to $10.21-$10.31 vs $10.15 Est
Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.97-$10.17 to $10.21-$10.31 vs $10.15 analyst estimate..
Benzinga Newsdesk
PRO
Quest Diagnostics Raises FY2026 Adj EPS Guidance from $11.05-$11.25 to $11.25-$11.35 vs $11.19 Est; Raises FY2026 Sales Guidance from $11.950B-$12.050B to $12.065B-$12.105B vs $12.001B Est
Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $11.05-$11.25 to $11.25-$11.35 vs $11.19 analyst estimate. Raises FY2026 sales outlook from $11.950 billion-$12.050 billion to $12.065 billion-$12.105
Benzinga Newsdesk
PRO
Quest Diagnostics Q3 Adj. EPS $3.00 Beats $2.86 Estimate, Sales $3.097B Beat $3.046B Estimate
Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $3.00 per share which beat the analyst consensus estimate of $2.86 by 4.9 percent. This is a 15.38 percent increase over earnings of $2.60 per share from the
Benzinga Newsdesk
Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is Winning
Quest Diagnostics (NYSE: DGX) stock jumps after Q2 earnings beat estimates and full-year 2026 guidance gets a boost.
Vandana Singh
Earnings Scheduled For July 23, 2026
Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report
Benzinga Insights
